Latest Frovatriptan Stories
PITTSBURGH, Aug. 17, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Endo Pharmaceuticals in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Frovatriptan Succinate EQ, 2.5 mg base tablets. This product is the generic version of Frova®, which is indicated for the treatment of symptoms associated with acute migraine...
CHADDS FORD, Pa., July 20 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its second quarter 2010 financial results on July 30, 2010 and will host a conference call and webcast at 10:00 a.m. ET that day to discuss these results. David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, and Alan Levin, executive vice president and chief financial officer and Blaine Davis, vice...
UNION CITY, Calif., June 11 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has received notification from the U.S. Food & Drug Administration (FDA) that the PDUFA date for Questcor's supplemental new drug application (sNDA) to approve Acthar for the treatment of infantile spasms (IS) has been extended to September 11, 2010. The FDA extended the PDUFA date in order to review information regarding labeling and potential post-approval...
CHADDS FORD, Pa., March 17 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, Mar. 23, 2010, at 10:15 a.m. EDT. David Holveck, president and chief executive officer of Endo, will review the company's products and development programs. The presentation will be webcast live and can be accessed from Endo's website at www.endo.com under the investors section. About Endo Endo...
CHADDS FORD, Pa., Aug. 12 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today the resignation of Nancy Wysenski, Endo chief operating officer, effective September 1, to attend to family matters. David Holveck, Endo's president and chief executive officer, stated: "I thank Nancy Wysenski for her contributions to the successful transition of Endo over the past two years. She has been instrumental in supporting our strong revenue growth, the diversification of the...
CHADDS FORD, Pa., May 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that the company is granting Alan Levin a sign-on award of 43,500 restricted stock units and an option to purchase 80,000 shares of Endo common stock in connection with his appointment as Endo's executive vice president and chief financial officer. These grants are being made outside of the Endo 2007 stock incentive plan but are subject to the terms and conditions of the plan with a...
CHADDS FORD, Pa., April 8 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its first quarter financial results on April 29, 2009 and will host a conference call and webcast at 10:30 a.m. ET that day to discuss these results. David P. Holveck, president and chief executive officer, Nancy J. Wysenski, chief operating officer, Ivan Gergel, M.D., executive vice president of research and development and Blaine Davis, vice president, corporate affairs will host the...
CHADDS FORD, Pa., March 23 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced the successful completion of its acquisition of Indevus Pharmaceuticals, Inc. Endo acquired Indevus through a tender offer and subsequent merger upon which Indevus became a wholly owned subsidiary of Endo. The common stock of Indevus ceased trading at market close on March 23, 2009 and has been converted into the right to receive $4.50 per Indevus share in cash and up to an additional...
CHADDS FORD, Pa., March 19 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced the successful completion of the tender offer by its wholly owned subsidiary, BTB Purchaser Inc., for all of the outstanding shares of common stock of Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV). American Stock Transfer & Trust Company, the depositary for the tender offer, has advised Endo that, as of 5 p.m., New York City time, on March 18, 2009, the expiration of the subsequent...
CHADDS FORD, Pa., Jan. 9 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that David Holveck, President and Chief Executive Officer of Endo, will present a corporate update at the J.P. Morgan 27th Annual Healthcare Conference on Wednesday, January 14, 2009 at 10:30 a.m. Pacific Time. The conference will be held January 12-15, 2009 in San Francisco. A link to a live audio Webcast of the presentation may be accessed on the Endo Website at www.endo.com. The...
